IndustryCompany release

BeOne raises 2026 revenue guidance to $6.9-7.0bn as BRUKINSA drives 34% Q3 growth

🇺🇸 BeOne Medicines Ltd. (ONC) · Thu 05 Nov 2026

BeOne Medicines reported third-quarter revenue of $1.9bn, with BRUKINSA sales of $1.4bn, and lifted its full-year revenue and operating income guidance.

BeOne Medicines reported third-quarter 2026 results on 5 November, posting total revenue of $1.9bn, a 34% rise on the same period a year earlier.

BRUKINSA (zanubrutinib) was the main driver, with sales reaching $1.4bn in the quarter. That figure accounts for the large majority of the company's total revenue for the period.

Following the results, BeOne raised its full-year 2026 revenue guidance to a range of $6.9bn to $7.0bn. The company also increased its operating income guidance. The summary available does not give the revised operating income figures or the previous guidance ranges.

BeOne also recorded a $22m impairment linked to its decision to stop promoting POBEVCY. No further detail on the reasons for that decision, or on the product's future availability, was provided in the material reviewed.

What it means for your team

  • Market-access teams should note BRUKINSA's scale in the BTK inhibitor market, as the product makes up most of BeOne's quarterly revenue.
  • The decision to stop promoting POBEVCY and the related $22m impairment may be relevant to anyone tracking the biosimilar's commercial presence, though the company's wider plans for it have not been detailed.
  • Detailed guidance breakdowns and the reasons behind the POBEVCY decision were not available, so teams should check the company's full results release before drawing conclusions.

Company's press release (SEC filing): BeOne Medicines Ltd. ↗

Article written by VigiEye from the official source (BeOne Medicines Ltd.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →